Zacks Investment Research upgraded shares of Edap Tms (NASDAQ:EDAP) from a sell rating to a hold rating in a research report released on Tuesday morning.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

Several other research analysts also recently issued reports on the company. TheStreet downgraded Edap Tms from a c rating to a d+ rating in a research report on Friday, September 28th. HC Wainwright restated a buy rating on shares of Edap Tms in a research report on Tuesday, September 4th. Finally, ValuEngine upgraded Edap Tms from a hold rating to a buy rating in a research report on Monday, July 16th.

Shares of Edap Tms stock traded down $0.09 during trading on Tuesday, hitting $2.41. 56,478 shares of the company were exchanged, compared to its average volume of 30,830. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.41 and a quick ratio of 1.97. Edap Tms has a fifty-two week low of $2.07 and a fifty-two week high of $4.25. The company has a market capitalization of $72.49 million, a P/E ratio of -241.00 and a beta of 0.74.

Edap Tms (NASDAQ:EDAP) last issued its quarterly earnings data on Wednesday, August 29th. The medical equipment provider reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01). Edap Tms had a negative return on equity of 2.66% and a negative net margin of 3.55%. The company had revenue of $10.14 million for the quarter, compared to analyst estimates of $10.74 million. As a group, research analysts expect that Edap Tms will post -0.03 EPS for the current fiscal year.

An institutional investor recently bought a new position in Edap Tms stock. Fosun International Ltd purchased a new stake in Edap Tms SA (NASDAQ:EDAP) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 170,627 shares of the medical equipment provider’s stock, valued at approximately $526,000. Fosun International Ltd owned about 0.59% of Edap Tms as of its most recent filing with the SEC. 8.13% of the stock is currently owned by hedge funds and other institutional investors.

Edap Tms Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

Recommended Story: Outstanding Shares and The Effect on Share Price

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with's FREE daily email newsletter.